恶性肿瘤相关性高钙血症中循环甲状旁腺激素相关蛋白（109 - 141）

Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia.

作者信息

Nagasaki K, Otsubo K, Kajimura N, Tanaka R, Watanabe H, Tachimori Y, Kato H, Yamaguchi H, Saito D, Watanabe T, Adachi I, Yamaguchi K

机构信息

Growth Factor Division, National Cancer Center Research Institute, Tokyo.

出版信息

Jpn J Clin Oncol. 1996 Feb;26(1):6-11. doi: 10.1093/oxfordjournals.jjco.a023180.

DOI:10.1093/oxfordjournals.jjco.a023180

PMID:8551669

Abstract

For differential diagnosis between hypercalcemia-induced bone metastasis and humoral hypercalcemia of malignancy (HHM), serum parathyroid hormone-related protein (PTHrP) concentrations were measured in normal subjects and patients with malignancy-associated hypercalcemia according to the presence or absence of bone metastasis, using a new sensitive PTHrP(109-141) radioimmunoassay system. The serum PTHrP(109-141) levels in all of 14 patients without bone metastasis were significantly higher than those in normal subjects. However, in four patients with hypercalcemia associated with bone metastasis the levels were nearly the same as those in normal subjects. The time course in two hypercalcemic patients with esophageal carcinoma revealed that serum PTHrP(109-141) levels were elevated before hypercalcemia developed and that changes in PTHrP(109-141) and corrected serum calcium levels were significantly correlated. These findings suggest that determination of serum PTHrP(109-141) may be clinically important not only for differential diagnosis of HHM but also as a useful predictive marker of hypercalcemia.

摘要

为了鉴别高钙血症所致骨转移与恶性肿瘤体液性高钙血症（HHM），我们使用一种新型的敏感甲状旁腺激素相关蛋白（PTHrP）（109 - 141）放射免疫分析系统，根据是否存在骨转移，对正常受试者及恶性肿瘤相关性高钙血症患者的血清甲状旁腺激素相关蛋白（PTHrP）浓度进行了测定。14例无骨转移患者的血清PTHrP（109 - 141）水平均显著高于正常受试者。然而，4例伴有骨转移的高钙血症患者的血清PTHrP（109 - 141）水平与正常受试者相近。两名食管癌高钙血症患者的病程显示，血清PTHrP（109 - 141）水平在高钙血症发生前升高，且PTHrP（109 - 141）与校正血清钙水平的变化显著相关。这些发现提示，测定血清PTHrP（109 - 141）不仅对HHM的鉴别诊断具有临床重要性，而且作为高钙血症的一种有用的预测标志物也具有重要意义。